AI platform reducing pharma compliance risks by 45% through federated learning that cross-references clinical submissions against global databases. Targets regulatory teams with tiered SaaS model.
ScriptSight addresses the $4.1B regulatory tech market with an AI-powered solution that automates pharmacovigilance compliance. By leveraging federated learning, it cross-references clinical trial documents against 120+ global databases while preserving data privacy – reducing compliance risks by 45% according to pilot data. Designed specifically for pharmaceutical regulatory teams.
Core functionality
Automated cross-referencing of clinical trial submissions against 120+ global pharmacovigilance databases using federated learning. Key features include real-time discrepancy flagging, blockchain-based audit trails, automated regulation updates, and risk scoring with remediation recommendations. Maintains data privacy by analyzing information without centralization.
Target user and segment
Regulatory affairs teams at mid-to-large pharmaceutical companies (50-500+ employees), contract research organizations (CROs), and clinical trial consultants. Primary focus on US/EU markets requiring GMP compliance, especially those managing complex Phase III trials or gene therapy submissions.
Recommended tech stack
- AI Core: Python/TensorFlow Federated
- Frontend: React.js
- Backend: Node.js
- Database: PostgreSQL with blockchain audit layer
- Infrastructure: AWS GovCloud (HIPAA/GxP compliant)
- Integration: FHIR API for health data interoperability
Estimated MVP hours and costs
Total development: 1,250 hours (€125,000 at €100/hour):
- Federated learning core: 400h (€40,000)
- Database integrations: 300h (€30,000)
- Compliance engine: 250h (€25,000)
- UI/Reporting: 200h (€20,000)
- Security/Testing: 100h (€10,000)
SWOT-analysis
Strengths:
- Unique federated approach preserves IP confidentiality
- 45% risk reduction validated by pilot data
- High switching costs post-implementation
Weaknesses:
- Complex regulatory approval requirements
- API dependency on third-party databases
- High implementation complexity
Opportunities:
- Medical device compliance expansion
- Regulatory agency partnerships
- Post-pandemic trial volume surge
Threats:
- Competition from Veeva (34% market share)
- Changing global regulations
- Data sovereignty conflicts
First 1000 customers strategy
Acquisition via:
- 10+ pharma compliance conference sponsorships
- LinkedIn ads targeting regulatory officers
- Co-marketing with GxP consultants
- Freemium access for small CROs
€1,200 customer acquisition cost targeting 7% conversion from trials. Timeline: 14 months.
Monetization
Business Model: Tiered SaaS + implementation fees
Pricing:
- Basic: €2,500/month (5 users)
- Enterprise: €8,000/month (unlimited)
- Implementation: €50,000 one-time
Break-even: Requires 18 enterprise or 55 basic clients to cover €300k annual costs. Achievable at 2.5% target segment penetration.
Core Team: 3 developers, 2 pharmacovigilance specialists, 1 compliance lawyer, 2 sales executives.
Market positioning and competitors
Operating in €4.1B regulatory tech market growing at 12.7% CAGR. Differentiated by federated learning enabling cross-database analysis without data centralization. Sales strategy leverages pharma industry veterans and compliance gap analysis. Key micro-niches:
- Gene therapy trial sponsors
- EU MDR compliance specialists
- Phase III trial consultants
